1. Home
  2. IFRX vs CLSD Comparison

IFRX vs CLSD Comparison

Compare IFRX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • CLSD
  • Stock Information
  • Founded
  • IFRX 2007
  • CLSD 2011
  • Country
  • IFRX Germany
  • CLSD United States
  • Employees
  • IFRX N/A
  • CLSD N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • CLSD Biotechnology: Pharmaceutical Preparations
  • Sector
  • IFRX Health Care
  • CLSD Health Care
  • Exchange
  • IFRX Nasdaq
  • CLSD Nasdaq
  • Market Cap
  • IFRX 56.4M
  • CLSD 59.1M
  • IPO Year
  • IFRX 2017
  • CLSD 2016
  • Fundamental
  • Price
  • IFRX $0.79
  • CLSD $0.80
  • Analyst Decision
  • IFRX Strong Buy
  • CLSD Strong Buy
  • Analyst Count
  • IFRX 4
  • CLSD 4
  • Target Price
  • IFRX $7.75
  • CLSD $4.75
  • AVG Volume (30 Days)
  • IFRX 282.5K
  • CLSD 402.9K
  • Earning Date
  • IFRX 08-07-2025
  • CLSD 08-11-2025
  • Dividend Yield
  • IFRX N/A
  • CLSD N/A
  • EPS Growth
  • IFRX N/A
  • CLSD N/A
  • EPS
  • IFRX N/A
  • CLSD N/A
  • Revenue
  • IFRX $140,242.00
  • CLSD $3,764,000.00
  • Revenue This Year
  • IFRX N/A
  • CLSD $60.52
  • Revenue Next Year
  • IFRX $6,309.47
  • CLSD $88.28
  • P/E Ratio
  • IFRX N/A
  • CLSD N/A
  • Revenue Growth
  • IFRX 30.90
  • CLSD N/A
  • 52 Week Low
  • IFRX $0.71
  • CLSD $0.70
  • 52 Week High
  • IFRX $2.82
  • CLSD $1.65
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 37.43
  • CLSD 50.60
  • Support Level
  • IFRX $0.78
  • CLSD $0.79
  • Resistance Level
  • IFRX $0.83
  • CLSD $0.82
  • Average True Range (ATR)
  • IFRX 0.04
  • CLSD 0.04
  • MACD
  • IFRX 0.03
  • CLSD 0.00
  • Stochastic Oscillator
  • IFRX 52.00
  • CLSD 52.50

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About CLSD Clearside Biomedical Inc.

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Share on Social Networks: